Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TENX | US
0.15
4.11%
Healthcare
Biotechnology
30/06/2024
16/10/2024
3.80
3.65
3.95
3.65
Tenax Therapeutics Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV) TNX-102 and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib) a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics Inc. and changed its name to Tenax Therapeutics Inc. in September 2014. Tenax Therapeutics Inc. was founded in 1967 and is based in Chapel Hill North Carolina.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
73.3%1 month
56.0%3 months
82.6%6 months
67.6%-
0.30
1.30
0.03
0.03
-0.14
-
-
-13.03M
13.25M
13.25M
-
-
-
-
-113.79
0.95
1.13
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.72
Range1M
0.72
Range3M
2.35
Rel. volume
1.72
Price X volume
214.25K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.94 | 14.48M | 13.45% | n/a | 3.49% |
IMNN | IMNN | Biotechnology | 0.9999 | 14.40M | 0.37% | n/a | 37.13% |
Aytu BioScience Inc | AYTU | Biotechnology | 2.2875 | 14.07M | -0.10% | n/a | 54.59% |
Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1249 | 13.74M | -0.16% | n/a | 21.43% |
Cingulate Inc. Common Stock | CING | Biotechnology | 4.4 | 13.39M | -1.12% | n/a | 10.72% |
Edesa Biotech Inc | EDSA | Biotechnology | 4.07 | 13.32M | -2.16% | n/a | 1.35% |
Evogene Ltd | EVGN | Biotechnology | 2.55 | 13.28M | 2.41% | n/a | 26.41% |
NRXP | NRXP | Biotechnology | 1.23 | 13.22M | 2.50% | n/a | -46.73% |
Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 6.9 | 13.12M | n/a | 0.50% | |
KTRA | KTRA | Biotechnology | 0.2299 | 12.80M | 1.28% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6542 | 9.49M | -5.19% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2051 | 3.68M | -6.82% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.09 | 2.84M | -0.91% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -0.99% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.42 | 0 | 2.63% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.21 | 0 | 3.19% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.5 | 0 | 1.42% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.05 | 0 | 6.06% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.77 | 0 | 1.65% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.14 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 1.30 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 82.57 | 72.92 | Par |
Debt to Equity | 0.03 | -1.24 | Expensive |
Debt to Assets | 0.03 | 0.25 | Cheaper |
Market Cap | 13.25M | 3.78B | Emerging |